CURRENT STATIN POSITIONS IN THE PREVENTION OF CARDIOVASCULAR EVENTS

Progression of the atherosclerotic process with the development of clinical manifestations is associated with an increased level of atherogenic fractions of lipids, primarily low-density lipoprotein cholesterol. The most studied group of lipid lowering drugs, which have proven their effectiveness in reducing cardiovascular morbidity and mortality, and the first choice drugs in the treatment of dyslipidemia are statins. The updated international guidelines for the treatment of dyslipidemia revised approaches to cardiovascular risk stratification and lipid lowering therapy tactics in different patient cohorts.

1. 2019 Rekomendacii ESC/EAS po lecheniyu dislipidemij: modifikaciya lipidov dlya snizheniya serdechnososudistogo riska. Rossijskij kardiologicheskij zhurnal. 2020;25(5):3826 doi:10.15829/1560-4071-2020-3826.

2. 2021 Rekomendacii ESC po profilaktike serdechno-sosudistyh zabolevanij v klinicheskoj praktike. Rossijskij kardiologicheskij zhurnal. 2022;27(7):5155. https://doi.org/10.15829/1560-4071-2022-5155.

3. 2022 Klinicheskie rekomendacii RKO «Narusheniya lipidnogo obmena». Proekt. https://noatero.ru

4. Arutyunov A.G., Arutyunov G.P. Korrekciya statinami serdechno-sosudistogo riska. Problemy i nereshennye voprosy na sovremennom etape. Izbrannye lekcii po terapii [sbornik lekcij] / [pod red. A.I. Martynova]. – Moskva: KST Interforum, 2015. – 112 s.

5. Averna M., Bruckert E., Drexel H. et al. Practical guidance for combination lipid-modifying therapy in highand very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis 2021 May; 325:99-109. doi: 10.1016/atherosclerosis2021.03.039.

6. Blankstein R., Budoff M.J., Shaw L.J. et al. Predictors of Coronary Heart Disease Events Among Asymptomatic Persons with Low Low-Density Lipoprotein Cholesterol: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58(4):364-374.

7. Blohm T.R., MacKenzie R.D. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys. 1959; 85: 245-249.

8. Forrester J.S. Redefining Normal Low-Density Lipoprotein CholesterolA Strategy to Unseat Coronary Disease as the Nation′s Leading Killer. J Am Coll Cardiol. 2010; 56(8):630-636.

9. Gilyarevsky S.R., Golshmid M.V. Influence of race on the choice of intervention tactics for prevention of cardiovascular diseases. EJIM. 2014; 01(03): 171-180.

10. Gofman J.W., Lindgren F., Elliott H, et al. The role of lipids and lipoproteins in atherosclerosis. Science. 1950; 111: 166-171.

11. Law M.R., Wald N.J. Risk factor thresholds: their existence under scrutiny. BMJ. 2002; 324: 1570-1576.

12. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk Factor Changes and Mortality Results. JAMA. 1982; 248 (12): 1465-1477.

13. O′Keefe Jr. J.H., Cordain L., Harris W.H., et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. Am Coll Cardiol. 2004;43(11):2142-2146.

14. Ray KK et al. Combination Lipid-Lowering Therapy in Very High–Risk Patients. Eur Heart J. 2022 Feb 22;43(8):830-833.

15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994; 344 (8934): 1383-1389.

16. Schmidt A.F., Carter J-P.L., Pearce L.S., et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2020. Issue 10. Art. No.: CD011748.

17. Vivencio Barrios, Jarkko Soronen, Angela M. Carter & Anastassia Anastassopoulou (2021) Lipid management across Europe in the real-world setting: a rapid evidence review, Current Medical Research and Opinion, 37:12, 20492059, https://doi:10.1080/03007995.2021.1973396.